Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of July 2026. The report discloses transactions by a Person Discharging Managerial Responsibilities (PDMR) in accordance with the UK Market Abuse Regulation. Haleon operates as a consumer health company with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive shareholding transactions.
Material Changes and Transactions
The filing details the vesting and subsequent sale of shares for Dawn Allen, Chief Financial Officer, on June 30, 2026:
- Acquisition: Allen acquired 283,193.15 ordinary shares via the Haleon Performance Share Plan (Buyout award). The price was listed as Nil, as these shares were awarded based on performance conditions met over the period ended December 31, 2025.
- Disposal: To cover tax liabilities, 133,300.73 ordinary shares were automatically sold on the London Stock Exchange (XLON) at a price of £3.523867 per share.
- Retention: The remaining shares are subject to retention requirements until shareholding thresholds are met and, for Executive Directors, for two years after receipt.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of general corporate risks. It notes that the award is subject to malus and clawback provisions. Performance targets and achievement levels are referenced as being disclosed in the 2025 Annual Report and Form 20-F.
Key Facts for Investor Verification
- Verify the total number of shares retained by Dawn Allen post-tax sale to assess compliance with shareholding requirements.
- Review the 2025 Annual Report and Form 20-F for details on the performance conditions that triggered this vesting.
- Confirm the current share price relative to the £3.523867 disposal price to understand the valuation context of the tax sale.